4.6 Article

Banff 2011 Meeting Report: New Concepts in Antibody-Mediated Rejection

期刊

AMERICAN JOURNAL OF TRANSPLANTATION
卷 12, 期 3, 页码 563-570

出版社

WILEY
DOI: 10.1111/j.1600-6143.2011.03926.x

关键词

Allograft rejection; allograft transplantation; antibody-mediated rejection; Banff classification

资金

  1. Astellas
  2. Novartis
  3. Roche
  4. Pfizer
  5. One Lambda
  6. CSL Behring
  7. Transpath
  8. Alexion
  9. Aperio
  10. Philips
  11. Omnyx
  12. University of Alberta
  13. National Kidney Foundation
  14. Renal Pathology Society
  15. Astellas Canada
  16. Genzyme
  17. ORS

向作者/读者索取更多资源

The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据